Skip to main content

Advertisement

SpringerLink
Log in

Therapy of Sjögren’s syndrome

  • Disease Specific Section
  • Published:
Springer Seminars in Immunopathology Aims and scope Submit manuscript

Conclusions

SS is a common disorder with significant morbidity that may involve multiple glandular and extraglandular sites with variable severity. A small but significant number of patients (5%) may eventually develop malignant lymphoma. In addition, some aspects of the syndrome are frequently encountered in patients with other autoimmune disorders. This multi-faceted presentation of the disorder demands refined measures for diagnosis and management.

The management of SS patients requires the co-operation of multiple medical disciplines and aims at alleviating symptoms and recognizing and treating complications. Despite significant progress in the understanding of the pathogenesis of SS, treatment of the syndrome remains empirical and symptomatic.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Atkinson JC, Fox PC (1993) Sjögren’s syndrome: oral and dental considerations. J Am Dent Assoc 124:74

    PubMed  CAS  Google Scholar 

  2. Boumpas D, Austin HA III, Vaughan EM, Klippel JH, Steinberg AD, Yaboro CH, Balow JE (1992) Controlled trial pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 340: 741

    Article  PubMed  CAS  Google Scholar 

  3. Constantopoulos SH, Tsianos EV, Moutsopoulos HM (1992) Pulmonary and gastrointestinal manifestations of Sjögren’s syndrome. Rheum Dis Clin North Am 18: 617

    PubMed  CAS  Google Scholar 

  4. Daniels T (1994) New approaches to treating dry mouth. In: Homma M, Sugai M, Toyo S, Miyasaka T, AkiyzLiki N (eds) Sjögren’s syndrome — State of the art. Kugler, Tokyo, pp 61–65

    Google Scholar 

  5. Fox RI (1992) Treatment of the patient with Sjögren’s syndrome. Rheum Dis Clin North Am 18: 699

    PubMed  CAS  Google Scholar 

  6. Gilbard JP, Rossi SR, Heyda KG, Dartt DA (1991) Stimulation of tear secretion and treatment of dry-eye disease with 3-isobutyl-l-methylxanthine. Arch Ophthalmol 109: 672

    PubMed  CAS  Google Scholar 

  7. Gunduz K, Ozdemir O (1994) Topical cyclosporin treatment of keratoconjunctivitis sicca in secondary Sjögren’s syndrome. Acta Ophthalmol (Copenh) 72: 438

    Article  CAS  Google Scholar 

  8. Haddad J, Deny P, Munz-Gotheil C, Ambrosini JC, Trinchet JC, Pateron D, Mai F, Callard P, Beau-grand M (1992) Lymphocytic sialadenitis of Sjögren’s syndrome associated with chronic hepatitis C virus liver disease. Lancet 339: 321

    Article  PubMed  CAS  Google Scholar 

  9. Kassan SS, Thomas TL, Moutsopoulos HM, Hoover R, Kimberly RP, Budman DR, Costa J, Decker JL, Chiised TM (1978) Increased risk of lymphoma in sicca syndrome. Ann Intern Med 89: 888

    PubMed  CAS  Google Scholar 

  10. La Corte R, Potena A, Bajocchi G, Fabbri L, Trotta F (1991) Increased bronchial responsiveness in primary Sjögren’s syndrome. A sign of tracheobronchial involvement. Clin Exp Rheumatol 9: 125

    Google Scholar 

  11. Linardaki G, Moutsopoulos HM (1997) The uncertain role of immunosuppressive agents in Sjögren’s syndrome. Cleve Clin J Med 64: 523

    PubMed  CAS  Google Scholar 

  12. Manoussakis MN, Moutsopoulos HM (2000) Sjögren’s syndrome: autoimmune epitheliitis. Baillieres Clin Rheumatol 14:73

    Article  CAS  Google Scholar 

  13. Moutsopoulos HM (1997) Sjögren’s syndrome therapy: future directions. J Rheumatol 24: 33

    Google Scholar 

  14. Moutsopoulos HM, Balow JE, Lawley TJ, Stahl NI, Antonovych TT, Chused TM (1978) Immune complex glomerulonephritis in sicca syndrome. Am J Med 64: 955

    Article  PubMed  CAS  Google Scholar 

  15. Moutsopoulos HM, Tzioufas AG (1994) Sjögren’s syndrome. In: Klippel JH, Dieppe PA (eds) Rheumatology. Mosby Year Book Europe, St. Louis, 6.27.21–26.27.22

    Google Scholar 

  16. Moutsopoulos NM, Routsias JG, Vlachoyiannopoulos PG, Tzioufas AG, Moutsopoulos HM (2000) B-cell epitopes of intracellular antigens: myth and reality. Mol Med 6: 141

    PubMed  CAS  Google Scholar 

  17. Nelson D (1994) What’s new in the treatment of dry eye? In: Homma M, Sugai M, Toyo S, Miyasaka T, Akiyzuki N (eds) Sjögren’s syndrome — State of the art. Kugler, Tokyo, pp 61–65

    Google Scholar 

  18. Nelson JD, Farris RL (1988) Sodium hyaluronate and polyvinyl alcohol artificial tear preparations. A comparison in patients with keratoconjunctivitis sicca. Arch Ophthalmol 106: 484

    PubMed  CAS  Google Scholar 

  19. Nelson JD, Gordon JF (1992) Topical fibronectin, in the treatment of keratoconjunctivitis sicca. Chiron Keratoconjunctivitis Sicca Study Group. Am J Ophthalmol 114: 441

    PubMed  CAS  Google Scholar 

  20. Newbrun E (1992) Preventing dental caries: breaking the chain of transmission. J Am Dent Assoc 123:55

    PubMed  CAS  Google Scholar 

  21. Newbrun E (1992) Preventing dental caries: current and prospective strategies. J Am Dent Assoc 123: 68

    PubMed  CAS  Google Scholar 

  22. Papiris S, Maniati M, Constantopoulos SH, Roussos CH, Moutsopoulos HM, Skopouli FN (1999) Lung involvement in primary Sjögren’s syndrome is mainly related to a small airway disease. Ann Rheum Dis 58: 61

    Article  PubMed  CAS  Google Scholar 

  23. Pavlidis NA, Drosos AA, Papadimitriou C, Talal N, Moutsopoulos HM (1992) Lymphoma in Sjögren’s syndrome. Med Pediatr Oncol 20: 279

    Article  PubMed  CAS  Google Scholar 

  24. Skopouli FN, Barbatis S, Moutsopoulos HM (1994) Liver involvement in primary Sjögren’s syndrome. Br J Rheumatol 33: 745

    Article  PubMed  CAS  Google Scholar 

  25. Ship JA, Fox PC, Michalek JE, Cummins MJ, Richards AB (1999) Treatment of primary Sjögren’s syndrome with low-dose natural human interferon-alpha administered by the oral mucosal route: a phase II clinical trial. IFN Protocol Study Group. J Interferon Cytokine Res 19: 943

    Article  PubMed  CAS  Google Scholar 

  26. Skopouli FN, Papanikolaou S, Malamou-Mitsi V, Papanikolaou N, Moutsopoulos HM (1994) Obstetric and gynaecological profile in patients with primary Sjögren’s syndrome. Ann Rheum Dis 53: 569

    Article  PubMed  CAS  Google Scholar 

  27. Skopouli FN, Talal A, Galanopoulou V, Tsampoulas, Drosos AA, Moutsopoulos HM (1990) Raynaud’s phenomenon in primary Sjögren’s syndrome. J Rheumatol 17: 618

    PubMed  CAS  Google Scholar 

  28. Talal N, Moutsopoulos HM, Kassan SS (1987) Sjögren’s syndrome. Clinical and immunological aspects. Springer, Berlin

    Google Scholar 

  29. Talal N, Sokoloff L, Barth WF (1967) Extrasalivary lymphoid abnormalities in Sjögren’s syndrome (reticulum cell sarcoma, “pseudolymphoma,” macroglobulinemia). Am J Med 43: 50

    Article  PubMed  CAS  Google Scholar 

  30. Tauber J, Grosser VA, Mardelli PG (1993) Improvement of squamous metaplasia following Aquasite TM treatment in patients with dry eye syndrome and in normal volunteers. Invest Ophthalmol Vis Sci 34:1742

    Google Scholar 

  31. Tsianos EV, Moutsopoulos HM (1989) Sjögren’s syndrome and the gut. Baillieres Clin Rheumatol 3: 357

    Article  PubMed  CAS  Google Scholar 

  32. Van der Reijden WA, Vissink A, Veerman EC, Amerongen AV (1999) Treatment of oral dryness related complaints (xerostomia) in Sjögren’s syndrome. Ann Rheum Dis 58: 465

    Article  PubMed  Google Scholar 

  33. Vitali C, Bombardieri S, Moutsopoulos HM, Balestrieri G, Bencivelli W, Bernstein RM, Bjerrum KB, Braga S, Coll J, Vita S de (1993) Preliminary criteria for the classification of Sjögren’s syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum 36: 340

    CAS  Google Scholar 

  34. Vivino FB, Al-Hashimi I, Khan Z, LeVeque FG, Salisbury PL III, Tran-Johnson TK, Muscoplat CC, Trivedi M, Goldlust B, Gallagher SC (1999) Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group. Arch Intern Med 159: 174

    Article  PubMed  CAS  Google Scholar 

  35. Vlachoyiannopoulos PG, Moutsopoulos HM (1997) Therapy of Sjögren’s syndrome. In: Putte L de, Furst D, Williams J, Riel P van (eds) Therapy of systemic rheumatic disorders. Marcel Dekker, New York, pp 615–628

    Google Scholar 

  36. Weiner H, Friedman A, Miller A (1994) Oral tolerance: immunogenetic mechanisms and treatment of animal and human organ-specific autoimmune disease by oral administration of autoantigens. Annu Rev Immunol 12: 809

    Article  PubMed  CAS  Google Scholar 

  37. Zulman J, Jaffe R, Talal N (1978) Evidence that the malignant lymphoma of Sjögren’s syndrome is a monoclonal B-cell neoplasm. N Engl J Med 299: 1215

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Oral Infection and Immunity Branch, National Institute of Dental Craniofacial Research, National Institutes of Health, BL. 30, Room 327, 30 Convent Dr., 20892, Bethesda, MD, USA

    Niki M. Moutsopoulos

  2. School of Medicine, Department of Pathophysiology, National University of Athens, Athens, Greece

    H. M. Moutsopoulos

Authors
  1. Niki M. Moutsopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. M. Moutsopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Moutsopoulos, N.M., Moutsopoulos, H.M. Therapy of Sjögren’s syndrome. Springer Semin Immunopathol 23, 131–145 (2001). https://doi.org/10.1007/s002810100070

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s002810100070

Keywords

Search

Navigation